自二十世纪九十年代以来国内外开始使用尿激酶溶栓治疗脑梗死,目前国内外多数学者认为,溶栓治疗确实有较好疗效,恢复好,住院时间短,明显降低了致残率,是最有前途的治疗方法。近年来,随着对尿激酶静脉溶栓临床研究的不断深入,在用药剂量的选择,时间窗的确定及并发症的防治等方面均取得了许多新进展。 Since the nineties of the twentieth century, urokinase thrombolytic therapy has been used to treat cerebral infarction in our country since the 90s of the 20th century. At present, most scholars at home and abroad think that thrombolytic therapy does have a good curative effect, good recovery, short hospital stay, significantly reduced morbidity, Is the most promising treatment. In recent years, with the urokinase intravenous thrombolytic clinical research continues to deepen in the choice of dosage, time window to determine and prevention and treatment of complications have made many new advances.